CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations5 currently firing — 1 · 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.83%Below 5Y avg (2.14%)
Annual Rate
CNY 0.28Paid annual
Payout Ratio
118.0%High
Payback Period
53.8 yr
Last Ex-Dividend
May 27, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.76BCNY410.63M · vs all stocks (USD)
Trailing P/E
38.56xvs Biotechnology peers
Revenue (TTM)
347.75MCNY51.65M · vs all stocks (USD)
Profit Margin
20.28%vs Biotechnology peers
Beta
0.0260xvs all stocks
52-Week Change
-30.87%vs all stocks
Market Capitalization
2.76BCNY410.63M · vs all stocks (USD)
Enterprise Value
2.05BCNY304.07M · vs all stocks (USD)
Trailing P/E
38.56xvs Biotechnology peers
Forward P/E
13.31xvs Biotechnology peers
Price to Sales (TTM)
7.78xvs Biotechnology peers
Price to Book (MRQ)
2.95xvs Biotechnology peers
Enterprise to Revenue
5.89xvs Biotechnology peers
Enterprise to EBITDA
25.38xvs Biotechnology peers
Gross Margin
82.65%vs Biotechnology peers
Profit Margin
20.28%vs Biotechnology peers
Operating Margin
17.19%vs Biotechnology peers
Return on Assets (TTM)
3.62%vs Biotechnology peers
Return on Equity (TTM)
7.75%vs Biotechnology peers
Revenue (TTM)
347.75MCNY51.65M · vs all stocks (USD)
Revenue per Share (TTM)
1.92CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-16.80%vs Biotechnology peers
Gross Profit (TTM)
300.81MCNY44.68M · vs all stocks (USD)
EBITDA (TTM)
71.18MCNY10.57M · vs all stocks (USD)
Net Income (TTM)
70.53MCNY10.48M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-44.60%vs Biotechnology peers
Operating Cash Flow (TTM)
71.02MCNY10.55M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
37.76MCNY5.61M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2800CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.83%vs all stocks
5-Year Average Dividend Yield
2.14%vs all stocks
Payout Ratio
117.95%vs Biotechnology peers
Revenue
364.14MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
51.43MCNYFY2025 · Dec 31, 2025Gross Profit
312.71MCNYFY2025 · Dec 31, 2025Operating Income
75.60MCNY11.23M · vs all stocks (USD)
Pre-tax Income
88.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
5.72MCNYFY2025 · Dec 31, 2025Net Income
82.41MCNYFY2025 · Dec 31, 2025EBIT
88.14MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
106.09MCNYFY2025 · Dec 31, 2025Research & Development
57.33MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
129.79MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.16MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
384.59KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
11.55KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
179.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
179.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
82.41MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
76.09MCNYFY2025 · Dec 31, 2025Free Cash Flow
67.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
61.99MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
82.41MCNYFY2025 · Dec 31, 2025Other Non-cash Items
27.43KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.64MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
5.29MCNYFY2025 · Dec 31, 2025Capital Expenditures
-9.03MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.08BCNYFY2025 · Dec 31, 2025Sale of Investments
1.02BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-65.17MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-81.71MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-81.71MCNYFY2025 · Dec 31, 2025Shares Outstanding
180.00MSharesUpdated Aug 20, 2026Float Shares
100.89MSharesUpdated Aug 20, 2026% Held by Insiders
44.57%vs all stocks
% Held by Institutions
2.71%vs all stocks
Total Cash (MRQ)
650.99MCNY96.69M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.67CNYUpdated Aug 20, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
8.42xvs Biotechnology peers
Book Value per Share (MRQ)
5.09CNYUpdated Aug 20, 2026Total Assets
984.62MCNY146.24M · vs all stocks (USD)
Total Current Assets
733.39MCNYFY2025 · Dec 31, 2025Total Liabilities
95.14MCNYFY2025 · Dec 31, 2025Total Non-current Assets
251.23MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
9.90MCNYFY2025 · Dec 31, 2025Total Current Liabilities
85.24MCNYFY2025 · Dec 31, 2025Cash
61.99MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
61.99MCNYFY2025 · Dec 31, 2025Other Short-term Investments
575.11MCNYFY2025 · Dec 31, 2025Accounts Receivable
57.18MCNYFY2025 · Dec 31, 2025Inventory
29.55MCNYFY2025 · Dec 31, 2025Accounts Payable
15.87MCNYFY2025 · Dec 31, 2025Other Current Liabilities
632.70KCNYFY2025 · Dec 31, 2025Common Stock (Book)
180.00MCNYFY2025 · Dec 31, 2025Retained Earnings
490.78MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
889.48MCNY132.11M · vs all stocks (USD)
Treasury Stock
49.92MCNYFY2025 · Dec 31, 202552-Week Low
13.37CNYUpdated Aug 20, 202652-Week High
23.36CNYUpdated Aug 20, 202652-Week Change
-30.87%vs all stocks
Beta
0.0260xvs all stocks
50-Day MA
14.64CNYUpdated Aug 20, 2026200-Day MA
18.57CNYUpdated Aug 20, 2026Avg 10-Day Volume
2.44MSharesUpdated Aug 20, 2026Avg 30-Day Volume
2.15MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.3900CNYUpdated Aug 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Focus Media Information Technology Co., Ltd.
5 interpretationsHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin ElevatedRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And Equity
Brilliance China Automotive Holdings Limited
4 interpretationsHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And Equity
Liaoning Chengda Biotechnology Co., Ltd.
4 interpretationsHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin ElevatedRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And Equity